• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Suven Life Sciences Limited — Updates, 11-12-2025: Press Release

    11-12-2025 | 10:14 am

    Suven Life Sciences hit 100% patient enrollment for Ropanicant's Phase-2b MDD trial, over two months early. This fast-tracks development, with topline data expected by May 2026, boosting prospects for a new depression treatment.

    No comments yet. Be the first to comment!

    All announcements from Suven Life Sciences Limited